Botulinium toxin in treatment of Parkinsonism
Objective: This review discusses the use of BT in various motor and non-motor symptoms of Parkinsonism. This review discusses the use of BT in various…A case of Parkinson’s Disease whose Daily Levodopa/Carbidopa Intestinal Gel dose has been determined by her spouse and prevented Long-term Fluctuations
Objective: To present a case of Parkinson’s disease (PD) whose daily levodopa/carbidopa intestinal gel (LCIG) dose has been determined by her spouse and prevented long-term…European Experience with Long-term Continuous Subcutaneous Apomorphine Infusions at Higher Doses
Objective: Outline European Union (EU) long-term experience with higher doses (≥6 mg/h or ≥100 mg/d) of continuous subcutaneous apomorphine infusion (CSAI). Background: The EU TOLEDO…Dietary Caffeic Acid Exhibits Neuroprotective and Neuromodulatory Effects in a Parkinsonian Rat Model by Mitigating Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis
Objective: This study investigated the neuroprotective and neuromodulatory effects of dietary caffeic acid (CA) in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonian rat model Background: Parkinson’s disease (PD)…Does the cerebellum compensate to enable motor learning in Parkinson’s Disease?
Objective: To test the causal relation between cerebellar function and learning in PD. Background: Neuroimaging studies reveal that people with Parkinson’s disease (PwPD) exhibit increased…Apomorphine Sublingual Film’s Efficacy in Elderly Patients with Parkinson’s Disease: Post-hoc Analysis of Study CTH-301
Objective: This study evaluated the efficacy of apomorphine sublingual film (SL-APO) in elderly (≥70 years) and younger (<70 years) patients over the long term. Background:…Multidimensional Assessment of Levodopa/Carbidopa/Entacapone Gel (LECIG) Therapy in Parkinson’s Disease: Perspectives of Patients, Clinicians, and Caregivers
Objective: To evaluate the impact of Levodopa/Entacapone/Carbidopa Gel (LECIG) therapy on Parkinson’s disease (PD) patients, their caregivers, and clinicians over six months. Background: Advanced PD…Patient And Clinician Perceptions Of Disease Improvement With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) In Advanced Parkinson’s – Data From The ELEGANCE Interim Analysis
Objective: To evaluate clinicians’ and patients’ views of the level of improvement in Parkinson’s disease (PD) achieved following up to two years of treatment with…Evaluation of Neuroprotective Effect of Terminalia macroptera on Rotenone Induced Parkinson’s Disease in Mice
Objective: This study investigates the neuroprotective effects of an aqueous extract of Terminalia macroptera (AETM) in a rotenone-induced Parkinsonism mouse model. Background: Parkinson’s disease (PD)…Chronic kidney disease, proteinuria, and mortality risk in patients with Parkinson’s disease: A longitudinal study
Objective: To investigate whether chronic kidney disease (CKD) and proteinuria are associated with mortality rates in patients with Parkinson's disease (PD), using data from a large…
- « Previous Page
- 1
- …
- 308
- 309
- 310
- 311
- 312
- …
- 1942
- Next Page »